Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?
AstraZeneca's best bets for the future are mostly biological treatments. And to prepare for its growing dependence on biotech drugs, the U.K. drugmaker is spending $285 million on a new biologics manufacturing operation.
AstraZeneca, trying to turn its sales performance around, has some biologics launches on the horizon. But to accommodate them, it needs more manufacturing capacity, and it thinks a new $285 million plant in Sweden will do the trick.
Having laid out plans last fall to expand a biologics plant in the U.S., AstraZeneca is now planning to build a new large-molecule filling facility in Sweden, adding up to 250 jobs in the process. The U.K. drugmaker says the new facility is part of a bigger plan for its biologics manufacturing, the details of which it will announce later.
AstraZeneca CEO Pascal Soriot is counting on the company's cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches.
AstraZeneca is digging through the genomes of 80,000 people in search of genes linked to cardiovascular diseases and diabetes. The project is a collaboration with the Montreal Heart Institute, which will genotype 80,000 samples from AstraZeneca's biobank of blood and tissue samples.
Abbott is teaming up with biotech heavyweight AstraZeneca to develop companion diagnostic tests for the company's investigational asthma therapy, a potentially fruitful alliance as Abbott rides the tailwinds of promising diagnostic sales.
More than three-fourths of practices have implemented a basic electronic health record system, according to HHS numbers, and around half now use advanced versions. EHR software vendors have direct access to--and the undivided attention of--those healthcare providers in a whole new way.
AstraZeneca paid a $15 million milestone payment to U.S.-based FibroGen as it works on moving to file for China FDA approval for roxadustat, an anemia candidate in clinical trials, as early as next year.
Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most.